| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 05/14/2008 | EP1921133A2 System for processing lipoaspirate cells |
| 05/14/2008 | EP1920780A1 Peptide compounds for the treatment of hyperexcitability disorders |
| 05/14/2008 | CN100387230C Pharmaceutical combination prepared by cannabis extract |
| 05/13/2008 | US7371896 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
| 05/13/2008 | US7371767 Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| 05/13/2008 | US7371756 Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts |
| 05/13/2008 | US7371747 Cyanoalkylamino derivatives as protease inhibitors |
| 05/13/2008 | US7371383 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders |
| 05/13/2008 | US7371382 Grafting antibodies to nucleic acids; anticancer agents, osteoporosis, vision defects, antiinflammatory agents, skin disorders |
| 05/13/2008 | US7371373 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 05/13/2008 | CA2468449C Improvements in benzodiazepine treatment by cholinesterase inhibitors |
| 05/13/2008 | CA2437814C Human monoclonal antibodies to fc alpha receptor (cd89) |
| 05/13/2008 | CA2410234C 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 05/08/2008 | WO2008054188A1 Synergistic pharmaceutical composition comprising lysine clonixinate and carisoprodol |
| 05/08/2008 | WO2008029152A3 Treatment of duchenne muscular dystrophy |
| 05/08/2008 | WO2008004127A3 Method for administering tolperisone |
| 05/08/2008 | US20080108809 Benzothiazole derivatives with activity as adenosine receptor ligands |
| 05/08/2008 | US20080108698 Nutrient Supplement and Use of the Same |
| 05/08/2008 | US20080108649 Bicyclic modulators of androgen receptor function |
| 05/08/2008 | US20080108590 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickenier; extended time high blood serum concentration; rapidly absorbed gel |
| 05/08/2008 | US20080107763 Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
| 05/08/2008 | US20080107627 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 05/08/2008 | US20080107603 Administering L-ergothioneine; Alzheimer's disease, multiple sclerosis, stroke, traumatic brain injury, spinal cord injuries |
| 05/07/2008 | EP1918279A2 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (ORL1) ligands for the treatment of pain |
| 05/07/2008 | EP1383774B1 Dihydroimidazo¬4,5-e indole and 7h-pyrrolo¬3,2-f quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 05/07/2008 | CN100386329C Substituted 3-amino-thieno(2,3-b)pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses |
| 05/06/2008 | US7368534 Myostatin and mimetics thereof |
| 05/06/2008 | US7368098 Use of biomolecular targets in the treatment and visualization of tumors |
| 05/02/2008 | WO2008050866A1 Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen |
| 05/02/2008 | WO2008050732A1 Iminopyridine derivative and use thereof |
| 05/02/2008 | WO2008030706A3 Anti-myostatin antibodies |
| 05/02/2008 | WO2008029168A3 Treatment of duchenne muscular dystrophy |
| 05/02/2008 | WO2008028888A3 Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting |
| 05/02/2008 | CA2667536A1 Highly purified type a botulinum toxin preparation from infant botulism pathogen |
| 05/02/2008 | CA2666606A1 Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative |
| 05/01/2008 | US20080103188 Novel bicyclic compounds as modulators of androgen receptor function |
| 05/01/2008 | US20080103180 CCR9 inhibitors and methods of use thereof |
| 05/01/2008 | US20080103137 antiinflammatory agents; 1H-imidazo[4,5-b]pyridin-7-indole-2-yl- derivatives; autoimmune and proliferative disorders; inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction; rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases |
| 05/01/2008 | US20080103120 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickenier; extended time high blood serum concentration; rapidly absorbed gel |
| 04/30/2008 | EP1915397A2 Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| 04/30/2008 | EP1915140A2 Novel use of peptide compounds for treating muscle pain |
| 04/30/2008 | EP1165613B1 Melanocortin receptor ligands |
| 04/30/2008 | CN100384841C Polymorphic forms of 1-4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 04/29/2008 | US7365172 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor; stimulate hematopoiesis; diabetes, rheumatoid arthritis, lupus, and multiple sclerosis |
| 04/29/2008 | US7365170 Reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents |
| 04/29/2008 | US7365083 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 04/29/2008 | US7365064 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 04/29/2008 | US7364852 Using presence of short expansion sequences in poly(A) binding protein II (PAB II) gene as diagnostic indicator of disease associated with polyalanine and protein accumulation in nucleus |
| 04/29/2008 | US7364722 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 04/29/2008 | CA2416492C Treatment of glycogen storage disease type ii |
| 04/29/2008 | CA2297732C Heterocyclic vinylethers against neurological disorders |
| 04/24/2008 | WO2008047821A1 Fused heterocyclic compound |
| 04/24/2008 | WO2008015139A3 Inhibitors of zinc proteases thioaryl substituted and their use |
| 04/24/2008 | WO2007060342A3 Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells |
| 04/24/2008 | US20080097109 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 04/24/2008 | US20080096954 Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method |
| 04/24/2008 | US20080096938 Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example |
| 04/24/2008 | US20080096847 More than one dopamine receptor agonist such as apomorphine, ropinirole, pramipexole, pergoline, cabergoline, SKF-81297; and/or more than one noradrenaline/dopamine precursor and/or more than one serotonin receptor agonist; spinal cord injuries; nervous system disorders; paraplegics or tetraplegics |
| 04/24/2008 | US20080096841 Using analogs of Lipid A such as Eritoran to treat or prevent mucositis, allograft/graft rejection, arteriosclerosis, atherosclerosis, hepatitis, asthma, and inflammatory bowel disease |
| 04/24/2008 | US20080096822 Use of the Neurotoxic Component of a Botulinum Toxin |
| 04/24/2008 | US20080095762 Glycoprotein compositions |
| 04/23/2008 | EP1912675A2 B-cell reduction using cd37-specific and cd20-specific binding molecules |
| 04/23/2008 | EP1912666A2 Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| 04/23/2008 | EP1615896B1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 04/23/2008 | EP0998459B1 Pyridine derivatives |
| 04/22/2008 | US7361787 Prophylaxis of respiratory disorders and therapy, also metod of synthesis and composition with PDE4 inhibitor, corticosteroid hibitor or anticholinergic agent |
| 04/22/2008 | US7361670 Amide derivatives as NMDA receptor antagonists |
| 04/22/2008 | US7361648 1-(4-{ethyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-4-methanesulfonyl-[1,4]diazepan-2-one; repiratory system disorders: asthma and chronic obstructive pulmonary disease; nervous system, muscular,urogenital, gastrointestinal disorders; antiallergens; side effect reduction |
| 04/22/2008 | US7361502 Nucleic acid molecule encoding a neuronal serine-threonine protein kinase |
| 04/22/2008 | CA2400447C Kinase inhibitors |
| 04/22/2008 | CA2299366C Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases |
| 04/17/2008 | WO2008044785A1 Material for improvement of cerebral blood flow, and use thereof |
| 04/17/2008 | WO2008044656A1 Imidazolidinone derivative |
| 04/17/2008 | WO2007146085A3 Creatine phosphate prodrugs, compositions and uses thereof |
| 04/17/2008 | US20080090874 Treatment of breakthrough pain in patients suffering from chronic low back pain |
| 04/17/2008 | US20080090846 Chemokine receptor binding heterocyclic compounds |
| 04/17/2008 | US20080090803 Fatty alcohol drug conjugates |
| 04/17/2008 | US20080090797 tert-Butyl[3-(4-phenyloxazolidin-2-on-3-yl)-4-(2-styryl)azetidin-2-on-1-yl]acetate; known as synthetic intermediates for the preparation of beta -lactam antibiotics; diuretic |
| 04/17/2008 | US20080090785 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents |
| 04/17/2008 | US20080090755 Follistatin Variant Polypeptide |
| 04/17/2008 | US20080090270 Neuronal binding protein for use tool in identifying modulators for prevention and treatment of nervous system disorders |
| 04/17/2008 | US20080089962 Nutritional composition for facilitating muscle pumps |
| 04/17/2008 | US20080089897 ActRIIB Fusion Polypeptides and Uses Therefor |
| 04/17/2008 | US20080089861 Therapeutic agent comprising memantine and dimethyl fumarate for use in prevention and treatment of autoimmune and nervous system disorders |
| 04/16/2008 | EP1911753A1 Spiro-cyclic compound |
| 04/16/2008 | EP1910380A1 Oxazolopyridine derivatives as sirtuin modulators |
| 04/16/2008 | EP1909910A1 Benzimidazole derivatives as sirtuin modulators |
| 04/16/2008 | EP1909787A1 Tizanidine compositions and methods of treatment using the compositions |
| 04/16/2008 | EP1349559B1 Compositions for inducing secretion of insulin-like growth factor-1 |
| 04/16/2008 | EP1108039B1 Elongase genes and uses thereof |
| 04/15/2008 | US7358354 Administering genetically engineered vectors to modulate lymphocytes; transfecting macrophages; used for prophylaxis or treatments for cancers or immune-related disorders |
| 04/15/2008 | US7358341 Secreted protein for use in diagnosis, prevention and treatment of thyroid gland disorders |
| 04/15/2008 | US7358333 Polypeptides of the IFNα-5 gene |
| 04/15/2008 | US7358276 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 04/15/2008 | US7358252 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever |
| 04/15/2008 | US7358245 Administering a therapeutically effective amount of a compound which is a cannabinoid receptor agonist, a pharmaceutically acceptable salt of the compound, an isomer of the compound, or a pharmaceutically acceptable salt of the isomer |
| 04/15/2008 | US7358243 1-[9-(3-Phenyl-allyl)-3,9 diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one; analgesic; great selectivity to mu receptor; analgesic; pain relief, drug dependence, alcoholism; side effect reduction |
| 04/15/2008 | US7358228 Methods of treating pain using neurotrophic factors |
| 04/15/2008 | CA2328920C Novel derivatives of 3,3-diphenylpropylamines |
| 04/10/2008 | WO2008041751A1 Pharmaceutical preparation for treating fibromyalgia |